Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.

Nature chemical biology - 1 Apr 2010

Li Jiannong, Rix Uwe, Fang Bin, Bai Yun, Edwards Arthur, Colinge Jacques, Bennett Keiryn L, Gao Jingchun, Song Lanxi, Eschrich Steven, Superti-Furga Giulio, Koomen John, Haura Eric B

Abstract excerpt

We describe a strategy for comprehending signaling pathways that are active in lung cancer cells and that are targeted by dasatinib using chemical proteomics to identify direct interacting proteins combined with immunoaffinity purification of tyrosine-phosphorylated peptides corresponding to acti...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Gene Knockdown Techniques
Share to Mass Spectrometry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphoproteins

Share to Protein-Tyrosine Kinases

Share to Proteomics

Share to Pyrimidines

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 20190765
DOI: 10.1038/nchembio.332
PMCID: PMC2842457

Genes

SRC
EGFR
FYN
DDR1
FRK
LCK
LYN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20190765-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.PMID 20190765Read ↗

Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.Semantic proximity Read ↗

Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.Semantic proximity Read ↗

Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.Semantic proximity Read ↗

Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.Semantic proximity Read ↗

Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapiesSemantic proximity Read ↗

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent ResistanceSemantic proximity Read ↗

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesSemantic proximity Read ↗

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.Semantic proximity Read ↗

Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.Semantic proximity Read ↗

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.Semantic proximity Read ↗

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.